Feb 15, 2018   SOURCE: PR NewsWire

Global Colorectal Cancer Forecast and Market Analysis 2017-2036: Avastin will Remain the Leading Targeted Therapy

DUBLIN, Feb. 15, 2018 /PRNewswire/ --

The "Colorectal Cancer Forecast and Market Analysis to 2036" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.

Market Snapshot

    --  Avastin will remain the leading targeted therapy in the colorectal
        cancer market through to 2024.
    --  Avastin in combination with FOLFOX remains the most commonly prescribed
        first-line treatment for Stage IV disease.
    --  As screening has not yet affected incidence rates, incident cases are
        predicted to increase between 2016 and 2036.
    --  Approved drugs seek label expansions to better compete as patent
        expiries threaten to erode branded sales of Avastin and Erbitux.
    --  Pipeline candidates will pursue novel mechanisms of action to
        distinguish themselves in an increasingly crowded market.

Key Topics Covered:

Forecast: Colorectal Cancer In The Us, Japan, And 5EU

    --  Executive Summary
    --  Recent Forecast Updates
    --  Market Dynamics
    --  Forecast And Future Trends
    --  Market Definition And Methodology
    --  Primary Research Methodology
    --  Bibliography
    --  Product Profile: Avastin
    --  Product Profile (Late Stage): Cotellic
    --  Product Profile: Cyramza
    --  Product Profile: Erbitux
    --  Product Profile: Keytruda
    --  Product Profile: Lonsurf
    --  Product Profile (Late Stage): Oncovax
    --  Product Profile: Opdivo
    --  Product Profile: Stivarga
    --  Product Profile: Ts-1
    --  Product Profile (Late Stage): Tecentriq
    --  Product Profile: Vectibix
    --  Product Profile: Zaltrap
    --  Product Profile (Late Stage): Binimetinib
    --  Product Profile (Late Stage): Lefitolimod
    --  Product Profile (Late Stage): Masitinib
    --  Product Profile (Late Stage): Napabucasin


Treatment: Colorectal Cancer In The Us, Japan, And 5EU 

    --  Executive Summary
    --  Primary Research Methodology
    --  Disease Definition And Diagnosis
    --  Patient Segmentation
    --  Current Treatment Options
    --  Prescribing Trends

Epidemiology: Colorectal Cancer In The Us, Japan, And 5EU 

    --  Executive Summary
    --  Disease Background
    --  Sources And Methodology
    --  Forecast
    --  Epidemiologist Insight
    --  Strengths And Limitations
    --  Appendix: Additional Sources

Marketed Drugs: Colorectal Cancer

    --  Executive Summary
    --  Product Overview
    --  Product Profile: Avastin
    --  Product Profile: Cyramza
    --  Product Profile: Erbitux
    --  Product Profile: Keytruda
    --  Product Profile: Lonsurf
    --  Product Profile: Opdivo
    --  Product Profile: Stivarga
    --  Product Profile: Ts-1
    --  Product Profile: Vectibix
    --  Product Profile: Zaltrap

Pipeline: Colorectal Cancer

    --  Executive Summary
    --  Clinical Pipeline Overview
    --  Product Profile (Late Stage): Cotellic
    --  Product Profile (Late Stage): Oncovax
    --  Product Profile (Late Stage): Tecentriq
    --  Product Profile (Late Stage): Binimetinib
    --  Product Profile (Late Stage): Encorafenib
    --  Product Profile (Late Stage): Lefitolimod
    --  Product Profile (Late Stage): Masitinib
    --  Product Profile (Late Stage): Napabucasin

For more information about this report visit https://www.researchandmarkets.com/research/tjfb6k/global_colorectal?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-colorectal-cancer-forecast-and-market-analysis-2017-2036-avastin-will-remain-the-leading-targeted-therapy-300599383.html

SOURCE Research and Markets